Anti-Mouse Delta-like protein 4 (DLL4) – Biotin

Recombinant mouse DLL4

This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Liquid

This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.

Research Use Only

2 – 8° C Wet Ice

HMD4-2 activity is directed against mouse Delta-like protein 4 (DLL4).

The Notch pathway is an intercellular signaling mechanism that controls cell fate and differentiation during embryonic and postnatal development^1,2. The pathway is highly conserved across species. Four mammalian Notch receptors (Notch 1-4) have been identified and can be activated by their ligands Jagged1, Jagged2, DLL1, DLL3, or DLL4. These ligands are transmembrane proteins that contain a Delta/Serrate/Lag-2 extracellular domain that is used for interactions with the Notch receptors². Receptor-ligand engagement triggers cleavage of the Notch receptor extracellular domain, leading to the release of the Notch intracellular domain which travels to the nucleus and affects target gene expression. Dysregulation of Notch signaling affects inflammation² as well as tumorigenesis and cancer growth^1,3. DLL4 is specifically involved in angiogenesis⁴ and retinal progenitor proliferation⁵.

HMD4-2 was generated by immunizing an Armenian hamster with recombinant mouse DLL4 and screening for antibodies that block rat Notch1-Fc binding to CHO cells expressing mouse DLL4^6,7. HMD4-2 blocks Notch1-Fc binding to DLL4-expressing CHO cells in a dose- dependent manner⁷. HMD4-2 does not cross-react with mouse DLL1, Jagged1, Jagged2, or human DLL4. DLL4 blockade suppresses solid tumor growth in mouse.

DLL4 is expressed in vascular endothelium. DLL4 is also expressed in the retina outer neuroblastic layer during embryogenesis.

Notch 1 and Notch 4

1. Fazio C, Ricciardiello L. Cell Death Dis. 7(12):e2515. 2016.
2. Sekine C, Nanki T, Yagita H. Arthritis Rheumatol. 66(10):2751-2761. 2014.
3. Mandula JK, Sierra-Mondragon RA, Jimenez RV, et al. Immunity. 57(5):1124-1140.e9. 2024.
4. Shutter JR, Scully S, Fan W, et al. Genes Dev. 14(11):1313-1318. 2000.
5. https://www.uniprot.org/uniprotkb/Q9JI71/entry
6. Moriyama Y, Sekine C, Koyanagi A, et al. Int Immunol. 20(6):763-773. 2008.
7.Yamanda S, Ebihara S, Asada M, et al. Blood. 113(15):3631-3639. 2009.
8. Sekine C, Moriyama Y, Koyanagi A, et al. Int Immunol. 21(3):295-301. 2009.
9. Sekine C, Koyanagi A, Koyama N, et al. Arthritis Res Ther. 14(2):R45. 2012.